We are live on ! Find out more
CELGZ

Celgene Corporation Contingent Value Rights

Delisted

CELGZ was delisted on the 29th of November, 2019.

26 hedge funds and large institutions have $31.3M invested in Celgene Corporation Contingent Value Rights in 2013 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 2626 (0)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

0% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 4

6% less capital invested

Capital invested by funds: $33.3M → $31.3M (-$2.02M)

14% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 7

Holders
26
Holders Change
Holders Change %
0%
% of All Funds
0.84%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
4
Increased
6
Reduced
7
Closed
4
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Royal Bank of Canada
26
Royal Bank of Canada
Ontario, Canada
-$23K -3,075 Closed
Wells Fargo
27
Wells Fargo
California
-$20K -2,596 -99%
PNC Financial Services Group
28
PNC Financial Services Group
Pennsylvania
+$524 +68 New

CELGZ Hedge Fund Activity: Q3 2013 in Review

26 of the 3,085 institutional investors tracked by Wall St. Rank reported a position in Celgene Corporation Contingent Value Rights (CELGZ) for Q3 2013, worth a combined $31.3M — down 6.1% from $33.3M a quarter earlier.

Fund positioning in CELGZ was balanced in Q3 2013: 4 funds opened new positions, 4 closed out, 6 added to existing stakes and 7 trimmed.

The largest buyer was Millennium Management, adding an estimated $2.44M. The largest seller was Camber Capital Management, exiting entirely with an estimated $4.88M sold.

  • 26 institutional investors held Celgene Corporation Contingent Value Rights (CELGZ) as of Q3 2013, unchanged from Q2 2013.
  • Funds reported $31.3M of Celgene Corporation Contingent Value Rights stock for Q3 2013, down 6.1% quarter-over-quarter.
  • 4 funds opened new Celgene Corporation Contingent Value Rights positions in Q3 2013 and 4 closed out, a net change of 0 holders.
  • The largest Celgene Corporation Contingent Value Rights buyer in Q3 2013 was Millennium Management, an estimated $2.44M added.
  • The largest Celgene Corporation Contingent Value Rights seller in Q3 2013 was Camber Capital Management, an estimated $4.88M sold.

Based on aggregated 13F filings for Q3 2013.